Opinion|Videos|September 12, 2024
Overview of Advanced Therapies in cGVHD
Medical experts discuss advanced therapies in cGVHD.
Advertisement
Video content above is prompted by the following:
- Dr Holtan:Both ruxolitinib and ibrutinib are approved for use in cases of cGVHD that have failed 1 or more lines of systemic therapy.
Briefly summarize and critique clinical trial data with ruxolitinib (REACH3) and ibrutinib (Miklos D, et al. Blood. 2017) in patients with cGVHD.
Comment on adverse effects most frequently seen with ruxolitinib and ibrutinib and how you manage them.
In which patients would you hesitate to use ruxolitinib or ibrutinib (eg, patients at risk of developing thrombocytopenia, etc)?
- Belumosudil is approved for treatment of cGVHD after failure of 2 or more systemic therapies. Can you elaborate on anti-inflammatory and antifibrotic properties of belumosudil and results from preclinical and human studies in reduction of fibrosis (Flynn R, et al. Blood. 2016)?
- How do these properties distinguish belumosudil from other targeted therapies for cGVHD?
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
4
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
5